Population scale data reveals the antidepressant effects of ketamine and other therapeutics approved for non-psychiatric indications

Abstract Current therapeutic approaches to depression fail for millions of patients due to lag in clinical response and non-adherence. Here we provide new support for the antidepressant effect of an anesthetic drug, ketamine, by Inverse-Frequency Analysis of eight million reports from the FDA Advers...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Isaac V. Cohen, Tigran Makunts, Rabia Atayee, Ruben Abagyan
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/29cfb95bdea44b70a57ebcd61bd9f670
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:29cfb95bdea44b70a57ebcd61bd9f670
record_format	dspace
spelling	oai:doaj.org-article:29cfb95bdea44b70a57ebcd61bd9f6702021-12-02T11:40:51ZPopulation scale data reveals the antidepressant effects of ketamine and other therapeutics approved for non-psychiatric indications10.1038/s41598-017-01590-x2045-2322https://doaj.org/article/29cfb95bdea44b70a57ebcd61bd9f6702017-05-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-01590-xhttps://doaj.org/toc/2045-2322Abstract Current therapeutic approaches to depression fail for millions of patients due to lag in clinical response and non-adherence. Here we provide new support for the antidepressant effect of an anesthetic drug, ketamine, by Inverse-Frequency Analysis of eight million reports from the FDA Adverse Effect Reporting System. The results of the examination of population scale data revealed that patients who received ketamine had significantly lower frequency of reports of depression than patients who took any other combination of drugs for pain. The analysis also revealed that patients who took ketamine had significantly lower frequency of reports of pain and opioid induced side effects, implying ketamine’s potential to act as a beneficial adjunct agent in pain management pharmacotherapy. Further, the Inverse-Frequency Analysis methodology provides robust statistical support for the antidepressant action of other currently approved therapeutics including diclofenac and minocycline.Isaac V. CohenTigran MakuntsRabia AtayeeRuben AbagyanNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 7, Iss 1, Pp 1-5 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Isaac V. Cohen Tigran Makunts Rabia Atayee Ruben Abagyan Population scale data reveals the antidepressant effects of ketamine and other therapeutics approved for non-psychiatric indications
description	Abstract Current therapeutic approaches to depression fail for millions of patients due to lag in clinical response and non-adherence. Here we provide new support for the antidepressant effect of an anesthetic drug, ketamine, by Inverse-Frequency Analysis of eight million reports from the FDA Adverse Effect Reporting System. The results of the examination of population scale data revealed that patients who received ketamine had significantly lower frequency of reports of depression than patients who took any other combination of drugs for pain. The analysis also revealed that patients who took ketamine had significantly lower frequency of reports of pain and opioid induced side effects, implying ketamine’s potential to act as a beneficial adjunct agent in pain management pharmacotherapy. Further, the Inverse-Frequency Analysis methodology provides robust statistical support for the antidepressant action of other currently approved therapeutics including diclofenac and minocycline.
format	article
author	Isaac V. Cohen Tigran Makunts Rabia Atayee Ruben Abagyan
author_facet	Isaac V. Cohen Tigran Makunts Rabia Atayee Ruben Abagyan
author_sort	Isaac V. Cohen
title	Population scale data reveals the antidepressant effects of ketamine and other therapeutics approved for non-psychiatric indications
title_short	Population scale data reveals the antidepressant effects of ketamine and other therapeutics approved for non-psychiatric indications
title_full	Population scale data reveals the antidepressant effects of ketamine and other therapeutics approved for non-psychiatric indications
title_fullStr	Population scale data reveals the antidepressant effects of ketamine and other therapeutics approved for non-psychiatric indications
title_full_unstemmed	Population scale data reveals the antidepressant effects of ketamine and other therapeutics approved for non-psychiatric indications
title_sort	population scale data reveals the antidepressant effects of ketamine and other therapeutics approved for non-psychiatric indications
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/29cfb95bdea44b70a57ebcd61bd9f670
work_keys_str_mv	AT isaacvcohen populationscaledatarevealstheantidepressanteffectsofketamineandothertherapeuticsapprovedfornonpsychiatricindications AT tigranmakunts populationscaledatarevealstheantidepressanteffectsofketamineandothertherapeuticsapprovedfornonpsychiatricindications AT rabiaatayee populationscaledatarevealstheantidepressanteffectsofketamineandothertherapeuticsapprovedfornonpsychiatricindications AT rubenabagyan populationscaledatarevealstheantidepressanteffectsofketamineandothertherapeuticsapprovedfornonpsychiatricindications
_version_	1718395508350779392

Population scale data reveals the antidepressant effects of ketamine and other therapeutics approved for non-psychiatric indications

Ejemplares similares